


The glycerophosphocholine acyltransferase Gpc1 contributes to phosphatidylcholine biosynthesis, long-term viability, and embedded hyphal growth in *Candida albicans*

Received for publication, May 21, 2023, and in revised form, November 28, 2023 Published, Papers in Press, December 10, 2023,

<https://doi.org/10.1016/j.jbc.2023.105543>

William R. King¹, Justin Singer¹, Mitchell Warman¹, Duncan Wilson², Bernard Hube³, Ida Lager⁴, and Jana Patton-Vogt^{1,*}

From the ¹Department of Biological Sciences, Duquesne University, Pittsburgh, Pennsylvania, USA; ²Department of Biosciences, University of Exeter, Exeter, England; ³Department of Microbial Pathogenicity Mechanisms, Leibniz Institute for Natural Products and Infection Biology Hans Knöll Institute, Jena, Germany; ⁴Department of Plant Breeding, Swedish University of Agricultural Sciences, Alnarp, Sweden

Reviewed by members of the JBC Editorial Board. Edited by George M. Carman

Candida albicans is a commensal fungus, opportunistic pathogen, and the most common cause of fungal infection in humans. The biosynthesis of phosphatidylcholine (PC), a major eukaryotic glycerophospholipid, occurs through two primary pathways. In *Saccharomyces cerevisiae* and some plants, a third PC synthesis pathway, the PC deacylation/reacylation pathway (PC-DRP), has been characterized. PC-DRP begins with the acylation of the lipid turnover product, glycerophosphocholine (GPC), by the GPC acyltransferase, Gpc1, to form Lyso-PC. Lyso-PC is then acylated by lysolipid acyltransferase, Lpt1, to produce PC. Importantly, GPC, the substrate for Gpc1, is a ubiquitous metabolite available within the host. GPC is imported by *C. albicans*, and deletion of the major GPC transporter, Git3, leads to decreased virulence in a murine model. Here we report that GPC can be directly acylated in *C. albicans* by the protein product of orf19.988, a homolog of ScGpc1. Through lipidomic studies, we show loss of Gpc1 leads to a decrease in PC levels. This decrease occurs in the absence of exogenous GPC, indicating that the impact on PC levels may be greater in the human host where GPC is available. A *gpc1*Δ/Δ strain exhibits several sensitivities to antifungals that target lipid metabolism. Furthermore, loss of Gpc1 results in both a hyphal growth defect in embedded conditions and a decrease in long-term cell viability. These results demonstrate for the first time the importance of Gpc1 and this alternative PC biosynthesis route (PC-DRP) to the physiology of a pathogenic fungus.

Candida albicans is a commensal fungus found in the gastrointestinal and genitourinary tract of most humans. However, it is also an opportunistic pathogen and the most frequent cause of fungal infection, primarily in immunocompromised individuals (1, 2). *C. albicans* causes an array of infections including vaginal, oral, and systemic. Systemic infection mortality rates can be upward of 40% (3). In addition, the rapid rise of antifungal resistance in *Candida* spp. is an

emerging issue leading to a demand for new therapeutic targets (4–6).

Several popular antifungals, like amphotericin B and fluconazole, target aspects of ergosterol metabolism, an essential plasma membrane lipid (4, 7, 8). Evidence demonstrating that lipid metabolism contributes to fungal virulence is continuing to grow (9). Lipids impact a variety of virulence mechanisms including drug resistance, biofilm formation, and the release of extracellular vesicles (10). Thus, aspects of lipid metabolism beyond ergosterol metabolism may provide other potential targets. Phosphatidylcholine (PC) is one of the most abundant phospholipids in eukaryotic membranes. Currently, *C. albicans* is known to synthesize PC by two biosynthetic pathways (Fig. 1), and a functional route for PC biosynthesis is required for *C. albicans* cell viability. The cytidine-diphosphate choline (CDP-choline) or Kennedy pathway converts CDP-choline plus diacylglycerol into PC as its final step (11, 12). Alternatively, the phosphatidylethanolamine (PE) methylation pathway produces PC through three sequential methylations of phosphatidylethanolamine (11, 12). In *Saccharomyces cerevisiae*, a third PC synthesis pathway known as PC deacylation/reacylation pathway (PC-DRP) has been characterized (13–15). PC-DRP begins with the deacylation of PC through B type phospholipases to produce glycerophosphocholine (GPC). GPC can then be acylated by a GPC acyltransferase known as Gpc1, followed by a second acylation by the lysophospholipid acyltransferase Ale1 (known as Lpt1 in *C. albicans*) (13, 16).

ScGpc1, catalyzing the committed step of PC-DRP, is the first characterized member of its protein family in fungi. ScGpc1 shares no obvious homology to other known acyltransferases such as the MBOATs, LPAATs, or DGATs (13, 15, 17). Potential Gpc1 homologs are found throughout fungi, plants, and animals, although there are no known homologs in humans or other chordates (15). There are potential ScGpc1 homologs in pathogenic fungi including *C. albicans*, *Candida auris*, *Candida glabrata*, and *Candida dubliniensis* (Table 1). However, *S. cerevisiae* and *C. albicans* are widely separated by evolution (18, 19). A number of proteins that share homology between these two organisms have altered function, including

* For correspondence: Jana Patton-Vogt, pattonvogt@duq.edu.

The *Gpc1* acyltransferase impacts cellular function




Figure 1. Simplified PC synthesis pathways in *C. albicans*. The PC deacylation/reacylation Pathway (PC-DRP) is indicated by red arrows. Internal GPC is produced by the import of extracellular GPC through Git3 or Git4 or the deacylation of PC to GPC by Plb1. GPC is acylated by Gpc1 to form LPC and by Lpt1 to form PC. The Kennedy pathway (left) and the PE methylation pathway (right) are indicated. Not all substrates and products are shown. CDP-Cho, cytidine-diphosphate choline; Cho, choline; DME, dimethyl-phosphatidylethanolamine; GPC, glycerophosphocholine; LPC, lyso-phosphatidylcholine; MME, mono-methyl phosphatidylethanolamine; PC, phosphatidylcholine; P-Cho, phosphocholine; PE, phosphatidylethanolamine; PLB, phospholipase B. Figure created in biorender.com.

proteins involved in lipid synthesis and PC metabolism (11). Particularly relevant to the work presented here, *S. cerevisiae* has a single GIT transporter, Git1, with greatest affinity for glycerophosphoinositol and low affinity for GPC. *C. albicans*, in contrast, has four GIT transporters, two of which, Git3 and Git4, transport GPC. Furthermore, the deletion of Git3 and Git4 leads to a decrease in its virulence in a bloodstream infection model (20).

Since GPC uptake impacts virulence and GPC is a prevalent metabolite in the human host, we undertook studies to determine if internalized GPC plays a role in PC biosynthesis through its direct acylation. Through *in vivo* radiolabeling and *in vitro* microsomal assays we show that orf19.988 is a *bona fide* GPC acyltransferase, the first identified in a pathogenic fungus. Through lipidomic studies, we demonstrate that loss of CaGpc1 leads to a decrease in overall PC levels, establishing PC-DRP as a contributor to bulk PC synthesis. Finally, we show that loss of Gpc1, and consequent disruption of PC-DRP, results in a variety of growth and drug sensitivity phenotypes, in addition to decreased stationary phase survival and decreased embedded hyphal growth. Overall, our results demonstrate the significance of Gpc1 and this alternative PC biosynthesis route (PC-DRP) to *C. albicans* physiology.

Table 1
ScGpc1 homologs among fungal pathogens

Species	% ID
<i>Saccharomyces cerevisiae</i>	100%
<i>Candida albicans</i>	45.2%
<i>Candida auris</i>	51.4%
<i>Candida dubliniensis</i>	45.9%
<i>Candida glabrata</i>	58.7%
<i>Candida parapsilosis</i>	42.4%

Percent identity of potential Gpc1 homologs to ScGpc1 determined by a BLASTp protein sequence alignment via NCBI using the default settings. % ID, percent identity.

Results

ScGpc1 homologs exist among pathogenic fungi

Homologs of ScGpc1 present in various pathogenic fungi, none of which have been characterized to this point. The five homologs examined (Table 1 and Fig. 2) exhibit a shared percent identity from 42% to 58%. The region corresponding to roughly 110 to 390 of *S. cerevisiae* is the most highly conserved among the species (Fig. 2). The *S. cerevisiae* protein is predicted to have eight transmembrane domains and is localized to the endoplasmic reticulum (21). The active site of ScGpc1 is not known but is the subject of current studies.

Among the homologs, *C. albicans* orf19.988 was previously identified in association with oral candidiasis. A deletion strain was created for those studies, but no additional characterization was published (22). Of note, the original study was performed prior to the identification of ScGPC1 as an acyltransferase. Given its homology with ScGpc1, we constructed a reintegrant strain utilizing the original *C. albicans* orf19.988 Δ/Δ mutant, now referred to as *gpc1* Δ/Δ , for the studies presented here.

Incorporation of ¹⁴C-choline-GPC into membrane PC is dependent upon Gpc1

To determine if a PC-DRP-type pathway exists in *C. albicans* and to examine its dependence upon Gpc1, we established a radiolabeling scheme. Cells grown to log phase in yeast nitrogen base (YNB) medium were provided with ¹⁴C-choline-GPC for 1 h. After this incubation, cells were fractionated into a PC (membrane) fraction and a trichloroacetic acid (TCA) extractable fraction. As shown in Figure 3A, 75% of label is incorporated into PC in the WT strain. In the *gpc1* Δ/Δ strain, little to no GPC is incorporated into PC. This phenotype is rescued in the reintegrant strain, returning the PC incorporation of the label to




Figure 2. GPC1 is conserved throughout pathogenic fungi. Sequence alignment of potential Gpc1 homologs. T-Coffee was used to create all sequence alignments using Jalview. Shading represents the percent identity.

The *Gpc1* acyltransferase impacts cellular function




Figure 3. Loss of *Gpc1* decreases GPC incorporation into PC. Indicated strains were grown to log phase, at which point radiolabeled ^{14}C -choline-GPC was added to the cultures. Cells were harvested after 1 h. Extracellular, intracellular, and membrane fractions were taken as described in the [Experimental procedures](#), and the percentage labeled in each fraction was detected by liquid scintillation counting. *A*, PC (membrane) fraction. *B*, water-soluble (TCA-extractable) fraction. *C*, extracellular fraction. *D*, TCA extractables were separated and analyzed *via* anion exchange chromatography as described. Experiments were performed in biological triplicate. A one-way ANOVA was used to establish significance. ** $p \leq 0.005$; *** $p \leq 0.0005$; **** $p \leq 0.0001$. ND, not determined.

roughly 60%. Although the product of *Gpc1* is lyso-PC, we do not detect it in these assays because lyso-PC is rapidly converted to PC. This is also the case in *S. cerevisiae* (13). The location of the label is reversed when comparing strains in the TCA extractable (water-soluble) fraction (Fig. 3B). While the WT and reintegrant strains exhibit less than 20% of the label in this fraction, 95% of the label is found to be TCA extractable in the *gpc1Δ/Δ* mutant. This indicates that GPC is imported into the cell but not incorporated into the membrane in the absence of *Gpc1*. Further analysis of the TCA-extractable fraction through anion exchange chromatography confirms that this label is primarily GPC (Fig. 3D). As a control we report extracellular counts to show that transport into the cell was similar over the course of the assay (Fig. 3C). Because the majority of label was incorporated into PC in the WT strain, accurate separation of the minor amounts of counts found in the TCA-extractable fraction was not possible. These results indicate that *Gpc1* significantly impacts the flux of GPC into PC through its acyltransferase activity.

CaGpc1 has *in vitro* GPC acyltransferase activity

In addition to our *in vivo* studies, *in vitro* enzymatic assays were performed as described (15). Briefly, microsomes

prepared from the indicated strains were incubated with ^{14}C -GPC along with the indicated acyl-CoA species. GPC acyltransferase activity was assessed by monitoring the production of labeled lipid (lyso-PC or PC). We tested four major acyl-CoA species common to *C. albicans*: 16:0, 18:1, 18:2, and 18:3. Over the course of this assay (Fig. 4A, column 2), WT utilized all acyl-CoA species roughly equivalently, producing 500 to 700 pmol of radiolabeled lipids. In contrast, the *gpc1Δ/Δ* produced minimal to no radiolabeled lipid, indicating that the strain has lost GPC acyltransferase activity. This activity can be minimally recovered in the reintegrant strain, which produces 70 to 90 pmol of radiolabeled lipid. This marginal recovery of activity in the reintegrant strain may be because there is only a single copy of the gene, as well as the gene being integrated on a nonnative locus. Nonetheless, the reintegrant activity is significantly higher than the null mutant. In our *in vivo* analysis of *Gpc1* activity (Fig. 3), the reintegrant strain recovers activity to a larger extent. The reason for this inconsistency across the two assays may be that the *in vivo* studies utilized trace amounts of radiolabel, a condition in which enzyme amount may not have been rate limiting for the reaction. In contrast, the *in vitro* enzymatic activity assay is optimized based on WT microsomes and utilized 0.5 mM of GPC and




Figure 4. *Gpc1* is required for GPC acylation *in vitro*. Microsomes were extracted from indicated strains and incubated with ^{14}C -choline-GPC along with stated acyl-CoA. Lipids were extracted, and total levels of LPC and PC produced were quantified via TLC. A, data represent the average of three technical and biological triplicates. B, WT data as shown in A. A *t* test was used to establish significance. * $p \leq 0.05$; ** $p \leq 0.005$; *** $p \leq 0.0005$; **** $p \leq 0.0001$.

0.4 mM of acyl-CoA. Figure 4B presents the acyl-CoA-specific data for WT in graph form and shows no significant difference between the acyl-CoA species. This result varies from what is seen in *ScGpc1*, which has a preference for 16:0-CoA (15). Overall, these data confirm *CaGpc1* is a functioning GPC acyltransferase, the first described in a pathogenic fungus.

Gpc1 contributes to total PC levels

In *S. cerevisiae*, PC-DRP has a PC recycling/remodeling function, where *Gpc1* remodels the acyl chains of PC to more saturated acyl chain species (13). To examine the impact of *Gpc1* (and PC-DRP) in *C. albicans*, we employed lipidomics. In these experiments, cells were not supplemented with exogenous GPC, so the substrate for *Gpc1* activity arose from turnover of PC by endogenous phospholipase B activity. In Figure 5A, we see that loss of *Gpc1* leads to 7% decrease in the overall PC levels as a total percentage of total glycerophospholipid species, with an increase in phosphatidylinositol and phosphatidylserine to compensate for this loss. Under these conditions, we did not detect any noticeable remodeling among PC species. These data are consistent with the finding in Figure 4 that *Gpc1* seems to have little preference for a particular acyl-CoA species. These data show that *Gpc1*

contributes significantly to PC membrane content in *C. albicans* even in the absence of exogenous GPC. Thus, under conditions lacking exogenous choline or GPC, when the PE methylation pathway is responsible for *de novo* synthesis, PC-DRP contributes to the cells' bulk PC levels. However, in the human host, where GPC is available, PC-DRP may be playing an even larger role. These results establish PC-DRP as a significant PC synthesis pathway in *C. albicans*.

Loss of *Gpc1* leads to increased sensitivity to drugs targeting lipid synthesis

Loss of *Gpc1* results in decreased levels of the abundant glycerophospholipid, PC. This finding led us to hypothesize that membrane homeostasis may be altered in *gpc1Δ/Δ* and that the strain might exhibit altered sensitivity to drugs targeting aspects of the three major lipid classes: sterols, sphingolipids, glycerophospholipids. In Figure 6A, we examine *gpc1Δ/Δ* sensitivity to a chronic exposure of ketoconazole, an imidazole that perturbs ergosterol synthesis by inhibiting lanosterol-14 synthetase (4). In the presence of the vehicle, all three strains grew similarly (Fig. 6A). However, in the presence of ketoconazole, *gpc1Δ/Δ* increased sensitivity. To examine if a triazole, another subclass of azoles, would have a similar

The *Gpc1* acyltransferase impacts cellular function




Figure 5. Loss of *Gpc1* decreases total PC levels but does not impact PC species. Indicated strains were grown to log phase in YNB, and cells were harvested and lipids were extracted as described in [Experimental procedures](#). Lipids were then analyzed using ESI-MS² at the Kansas Lipidomics Center. *A*, relative abundance of indicated glycerophospholipids. *B*, relative abundance of indicated PC species. Experiment was performed in biological quadruplicate. A one-way ANOVA was used to establish significance. *** $p \leq 0.0005$; **** $p \leq 0.0001$. LPC, lysophosphatidylcholine; LPE, lysophosphatidylethanolamine; PA, phosphatidic acid; PC, phosphatidylcholine; PE, phosphatidylethanolamine; PG, phosphatidylglycerol; PI, phosphatidylinositol; PS, phosphatidylserine.

phenotype, we examined a *gpc1Δ/Δ* sensitivity to fluconazole and found it behaved similar to WT, despite the drug inhibiting the same enzyme as ketoconazole. One interpretation of these results is that at the drug concentrations employed, only ketoconazole impacts ergosterol levels enough to lead to increased sensitivity in the absence of *Gpc1*, where PC levels are also decreased. The two drugs are often applied at different concentrations in the literature, suggesting that they do not have identical properties (23, 24).

To examine sensitivities to perturbations in sphingolipid and glycerophospholipid metabolism, *gpc1Δ/Δ* growth was assessed in the presence of myriocin and miltefosine, respectively. Both myriocin and miltefosine are highly toxic. For these experiments we chose acute instead of chronic drug exposure followed by assaying the ability to grow after reinoculation (25). This is a commonly used alternate approach to colony-forming units for measurements based on the single output of turbidity in a high-throughput format (26, 27). Strains were exposed to the vehicle, myriocin (Fig. 6B), or miltefosine (Fig. 6C) for 1 h, washed and

then reinoculated into fresh medium. Their regrowth was measured after 20 h. In Figure 6B, we examine sensitivity of *gpc1Δ/Δ* to myriocin, which targets sphingolipid biosynthesis by inhibiting serine palmitoyltransferase, the first step in *de novo* sphingolipid biosynthesis (28). When treated with the vehicle, we do not see any significant changes in the strains upon regrowth (Fig. 6B). However, when sphingolipid biosynthesis is inhibited using myriocin, *gpc1Δ/Δ* grows to roughly 60% of WT after 20 h, indicating increased sensitivity to the drug.

Lastly, we examined miltefosine (Fig. 6C). Miltefosine is used to treat leishmaniasis, but it also has antifungal properties. Miltefosine is an alkylphosphocholine and is structurally like lyso-PC. Its mechanism of action is not fully characterized, although it has been shown to impact membrane lipids, including inhibiting PC biosynthesis (29–31). Owing to the documented effects of miltefosine on PC biosynthesis, and its similar structure to lyso-PC (the product of *Gpc1*), we examined sensitivity of *gpc1Δ/Δ* to this drug. When exposed to a vehicle control, regrowth among the strains does not differ (Fig. 6C). However, when




Figure 6. Loss of *Gpc1* increases sensitivity perturbations in lipid synthesis. *A*, The indicated strains were grown in YPD with dimethyl sulfoxide (vehicle), 8 μ M fluconazole, 8.5 mM caffeine, or 26 μ M ketoconazole, on a Molecular Devices SpectraMax i3, 30 °C with intermittent shaking. Data are displayed as the mean and standard deviation of at least three replicates per strain. Significance was established using a *t* test. **p* \leq 0.0001. *B*, indicated strains were grown to log phase in YPD then exposed to dimethyl sulfoxide (vehicle) or 15 μ g/ml of myriocin for 1 h. Cells were then washed and restarted at an A_{600nm} of 0.1 and allowed to grow for 20 h. *C*, same as *B* except treated with ethanol (vehicle) or 7 μ g/ml miltefosine. Experiments were performed in at least biological triplicate. A one-way ANOVA was used to establish significance. ***p* \leq 0.005; ****p* \leq 0.0005; *****p* \leq 0.0001.

exposed to an acute dose of miltefosine, regrowth in *gpc1Δ/Δ* is significantly reduced. This sensitivity to the perturbations caused by miltefosine is rescued in the reintegrant strain.

To confirm that the drug sensitivities seen in Figure 6, *A* and *B* were not attributable to a general permeability defect, we examined the *gpc1Δ/Δ* strain in presence of caffeine (Fig. 6*A*, far right panel). Caffeine inhibits the major nutrient regulator target of rapamycin complex 1. The *gpc1Δ/Δ* mutant did not display a sensitivity to caffeine. These results indicate that loss of *Gpc1* leads to sensitivities to a variety of membrane stressors, including perturbations in ergosterol, sphingolipid, and glycerophospholipid metabolism.

Transcriptional regulation of *GPC1*

Given the impact of *Gpc1* on PC content, we examined *GPC1* messenger RNA levels in response to perturbations that might impact PC biosynthesis. Choline supplementation impacts PC synthesis through the Kennedy pathway, and we predicted that provision of GPC may also impact transcription. As shown in

Figure 7*A*, neither had an effect. We additionally tested *GPC1* transcript in strains bearing mutations in other pathways for PC biosynthesis. The *pem1Δ/Δpem2Δ/Δ* and *ept1Δ/Δ* strains, strains that block the PE methylation and Kennedy pathway, respectively, were employed. A *pem1Δ/Δpem2Δ/Δ* mutant is a choline auxotroph because choline can only be synthesized *de novo* through the stepwise methylation of ethanolamine as occurs in the PE methylation pathway. Thus, the mutant cells need an exogenous source of choline. The CDP-choline and PC-DRP pathways rely on turnover of existing PC and/or exogenous sources of choline or GPC, respectively (both available in the human host), to synthesize PC. For culturing *pem1Δ/Δpem2Δ/Δ*, we provided choline instead of GPC to simplify the interpretation of *Gpc1* regulation. We did not detect any changes in *GPC1* expression (Fig. 7*A*) upon loss of either the methylation pathway or the Kennedy pathway.

Because GPC transport and degradation are regulated by phosphate availability, we examined *GPC1* expression under low-phosphate conditions. We did not detect any changes in

The *Gpc1* acyltransferase impacts cellular function




Figure 7. *GPC1* is upregulated at 37 °C, acidic pH, and during heavy metal stress. WT cells were grown in YNB to log phase. RNA was extracted and real-time quantitative RT-PCR was performed as described under “Experimental procedures.” Each symbol represents a biological replicate performed in technical triplicate. *A*, WT cells were grown to log in YNB with the addition of indicated 50 μM choline or GPC. When examining WT in comparison with *ept1Δ/Δ* or *pem1Δ/Δpem2Δ/Δ* all strains were supplemented with 50 μM of choline. For phosphate studies, 200 μM KH₂PO₄ (*low*) versus 10 mM KH₂PO₄ (*high*) was supplemented in phosphate-free YNB. *B*, WT cells were grown at 30 °C to log phase and then shifted to 30 °C or 37 °C for 1 h. *C*, WT cells were grown in YNB buffered to stated pH for 6 h. *D*, WT strains were exposed to CdCl₂ for 1 h at 0.5 mM. Each data point represents the average of a technical triplicate for each biological replicate. *C*, choline; GPC, glycerophosphocholine; *n.s*, not significant; YNB, yeast nitrogen base. A *t* test was performed. **p* ≤ 0.05; ***p* ≤ 0.005.

expression (Fig. 7A). We also examined *GPC1* expression under various physiological conditions. In the presence of serum, we did not see a change. However, there was an increase in transcript at 37 °C as compared with 30 °C, and at pH 4 as compared with pH 7 (Fig. 7B). Finally, we examined *GPC1* transcript in the presence of CdCl₂, a heavy metal stress known to impact lipid metabolism (32). Upon CdCl₂ treatment we see a roughly 3-fold increase in message, consistent with a previous microarray study (33).

Loss of *Gpc1* causes a hyphal growth defect under embedded growth conditions

A variety of environmental signals can trigger hyphal growth in *C. albicans* including pH, temperature, nutrient deprivation, and the presence of serum (34). Hyphal growth is regulated by several complex signaling pathways including the Cek1 MAPK, cAMP-PKA, pH response, Hog1 MAPK, and the Tup1-mediated negative regulatory pathways (35). However, in embedded conditions at 25 °C, *C. albicans* produces hyphae in a process involving the transcription factor Czf1 (36, 37).

Czf1 regulation of hyphal growth in embedded conditions varies uniquely from other hyphal growth triggers (35, 37). We did not detect any defects in filamentous growth in the *gpc1Δ/Δ* strain when grown on spider medium or in the presence of serum. However, in embedded conditions, as shown in Figure 8, less than 10% of *gpc1Δ/Δ* colonies produced hyphae, in comparison with roughly 75% of WT colonies. This phenotype was restored in the reintegrant, where over 60% of colonies produce hyphae.

Gpc1 is required for long-term viability in stationary phase

In *S. cerevisiae*, loss of *Gpc1* causes a loss of viability when grown long term in stationary phase (13). To examine if this phenotype also occurred in *C. albicans*, we used propidium iodide (PI) staining coupled with regrowth to monitor cell death. Cells were grown to stationary phase and allowed to grow for 5 days. Cells were harvested from each culture for PI staining, and an aliquot was used for a recultivation experiment to monitor loss of viability by measuring regrowth (27). No noticeable growth defects were identified prior to 5 days.




Figure 8. Loss of Gpc1 causes a defect in hyphal growth under embedded conditions. Indicated strains were grown embedded in yeast peptone sucrose medium for 4 days at 25 °C. **A**, percentage of hyphae-producing colonies in biological triplicate ($n = 100$ cells per plate). **B**, representative images were taken using a Nikon SMZ25 stereo-compound microscope with the 2 X SHR Plan Apo objective and the NIS Elements software. Experiments were performed in biological triplicate. A one-way ANOVA was used to establish significance. **** $p \leq 0.0001$.

After 5 days (Fig. 9A), *gpc1Δ/Δ* had nearly 95% PI positivity in comparison with roughly 10% in the WT. Example images from these experiments are shown in Figure 9B. For regrowth experiments, new cultures were inoculated at A_{600nm} of 0.1 and allowed to grow for 20 h. In Figure 9C, we see that *gpc1Δ/Δ* displays much less regrowth at 20 h in comparison with the WT and reintegrant strains. These results demonstrate that loss of Gpc1 decreases stationary phase viability.

Discussion

Through a combination of *in vivo* radiolabeling, *in vitro* enzyme assays, and lipidomics studies, we report that Gpc1 is a functioning GPC acyltransferase in *C. albicans*, establishing this third PC biosynthetic route (PC-DRP) in a pathogenic fungus (Figs. 3–5). A role for Gpc1 in membrane homeostasis is further indicated by the finding that loss of Gpc1 leads to sensitivity to drugs targeting lipid biosynthesis (Fig. 5). Evidence for the physiological importance of Gpc1 (and PC-DRP) is provided by the fact that loss of Gpc1 leads to a decrease in embedded hyphal growth (Fig. 8) and decreased stationary phase viability (Fig. 9).

The availability of GPC within the human host as well as its rapid uptake *via* the Git3 and Git4 transporters highlights its physiological relevance for the organism (20). Indeed, when

GPC import is inhibited, there is decreased virulence in a bloodstream infection model (20). Plb1 and Plb5, enzymes that produce GPC from PC, are known virulence factors in *C. albicans* (38–41). Plb1 is secreted from the fungus and is thought to be required for host cell penetration by deacylating phospholipids and thereby producing metabolites such as GPC at sites of infection (39). Thus, when considering GPC availability, it is important to note that GPC is produced by both fungal and host phospholipase activity acting on PC (42). Quantitative metabolic studies on GPC in the human host are sparse, but serum levels reportedly range from 3 to 35 μM (43, 44). Given that the kidney is a site of disseminated candidiasis (45), it is noteworthy that GPC is also a renal osmolyte reported to be present in renal cells at roughly 18 nmoles/mg protein (46–49). The GPC content in other host microenvironments is unknown and likely dynamic, because GPC is liberated through phospholipase-mediated PC hydrolysis (50–52).

Once imported into *C. albicans*, GPC has several metabolic fates. Previous studies have established that GPC can be degraded by phosphodiesterases such as Gde1 and used as both choline and phosphate sources by the cell (11, 20). The import and degradation of GPC are upregulated by phosphate limitation through the PHO regulon, the phosphate

The *Gpc1* acyltransferase impacts cellular function




Figure 9. Loss of *Gpc1* decreases stationary phase viability. Indicated strains were grown in yeast nitrogen base for 5 days at which point an aliquot was stained with propidium iodide (PI) and an aliquot was used to restart cultures in fresh medium. **A**, quantification of PI-positive cells. Points represent percentages of each biological replicate that was PI positive ($n = 200$ cells). **B**, representative images of PI-stained cells. Overlay of red and brightfield propidium iodide stain using Brightfield. Nikon TiE microscope, 100x objective. The scale bar represents 20 μm . **C**, indicated strains were grown in yeast nitrogen base for 5 days. An aliquot was reinoculated in fresh medium at an $A_{600\text{nm}}$ of 0.1 and grown for 20 h. Experiments were performed in biological triplicate. A one-way ANOVA was used to establish significance. **** $p \leq 0.0001$.

homeostatic mechanism in *C. albicans*. However, even under phosphate-replete conditions, GPC is still transported into the cell at a high rate (Fig. 3, (20, 53)). In this study we have now established GPC can also be directly acylated by *Gpc1* and shunted into PC-DRP to produce PC.

Disruption of the PEMT pathway (*pem1Δ/Δpem2Δ/Δ* strain) leads to choline auxotrophy, indicating the absolute requirement for a functional PC biosynthetic pathway to maintain viability. Previous studies have shown that, in addition to choline, the auxotrophy can be satisfied by GPC or lysoPC (11). GPC and lysoPC could flux into the PC-DRP pathway described here. However, available GPC might also be catabolized to glycerol-3-phosphate and choline and the resulting choline used by the CDP-choline pathway. The relative flux between the pathways will likely depend upon nutritional conditions. For example, phosphate stress leads to upregulation of the *Gde1* glycerophosphodiesterase that hydrolyzes GPC to glycerol-3-phosphate and free choline (20, 54).

Since a functional route for PC biosynthesis is required for *C. albicans* cell viability, studies examining the importance of each to cell virulence must be performed in the presence of the alternate pathway. Loss of *Ept1* (ethanolamine phosphotransferase 1), the final step in the Kennedy pathway for both PE and PC biosynthesis, leads to a decreased fungal burden in a mouse model (11). Surprisingly, loss of *Pem1* and *Pem2* (phosphatidylethanolamine methyltransferase 1 and 2), which inhibits the PE methylation pathway but maintains PC synthesis *via* the Kennedy pathway, leads to hypervirulence in a mouse model, a finding the authors attributed to a buildup of PE (11, 55). Overexpression of *EPT1* also leads to hypervirulence (11). Since *C. albicans* does not transport sufficient

ethanolamine (for PE biosynthesis) from the host to support virulence in the absence of *de novo* PE synthesis pathways (56), it is likely that upregulation of PC synthesis, not PE synthesis, *via* the CDP-choline pathway is the reason for the hypervirulence in this case.

Here we report that loss of *Gpc1* leads to a decrease in PC content, even in the absence of exogenously supplied GPC. Thus, blocking PC resynthesis (*via* PC-DRP) following its deacylation *via* normal turnover is important for maintaining PC levels, even in the absence of external sources of GPC. As a result, the lipidomics studies presented (Fig. 5) here likely underestimate the impact of PC-DRP on PC levels in the human host, where GPC is available. Future studies examining the impact of loss of *Gpc1* and other genes of the PC-DRP pathway on virulence will provide key information regarding the importance of this pathway for pathogenesis. Although many genes in phospholipid metabolism are conserved between yeast and humans (12, 57), *Gpc1* and the GPC transporters *Git3* and *Git4* are not, suggesting that this aspect of GPC metabolism may provide potential targets for antifungal agents (15, 20).

While we have identified clear phenotypes associated with loss of *Gpc1* (Figs. 3–9), the exact mechanisms underlying those observations are unknown and will be the target of future studies. Interestingly, the direct acylation of GPC leading to PC biosynthesis has also been characterized in bacterial human pathogens within the Mitis Group Streptococci (58). Those findings in conjunction with this work suggest that the acylation of host GPC for PC biosynthesis may be a more common metabolic strategy for human pathogens than previously realized.

Experimental procedures

Strains, media, and growth conditions

The *C. albicans* strains and plasmids used in this study are presented in Table 2. Strains were maintained aerobically at 30 °C with shaking or on a roller drum. Growth was monitored with a Thermo Scientific BioMate160 spectrophotometer via $A_{600\text{nm}}$ measurements. Strains were maintained on yeast peptone dextrose (YPD). YNB medium with 2% glucose was prepared as described (13, 59).

Construction of the *gpc1Δ/Δ* strain was described (22). The original knockout strain was reconfirmed via PCR using primers that bound outside of original locus of orf19.988 and amplified the selective markers used for the deletion of the alleles. Additionally, in the *gpc1Δ/Δ* strain there was no amplification of orf19.988 when using primers that bind within orf19.988. For creation of the *gpc1Δ/Δ+GPC1* reintegrant strain, the open reading frame, orf19.988, with an additional 500 base pairs upstream and 250 downstream was amplified from pDDB78/GPC1 with Dreamtaq polymerase with primers containing HindIII and XhoI sites. The PCR product was digested with HindIII and XhoI in parallel with Clp10 and then gel extracted using a Zymoclean gel DNA recovery kit (Catalog Number D4008). Insert and vector were then ligated and 5 μl was transformed into *E. coli* DH5alpha. Positive clones were selected for on LB agar containing 100 μg/ml ampicillin and confirmed through digestions with HindIII and XhoI. The final plasmid was then digested with NcoI prior to transformation into *gpc1Δ/Δ* where it integrates at the *RPS10* locus (60). Positive clones were selected on YNB lacking uracil. Integration was verified by PCR confirming the amplification of orf19.988 at the expected locus.

Growth analyses

Growth curves were obtained by inoculating a 96-well plate at $A_{600\text{nm}} = 0.1$ from overnight cultures in YPD. Strains were exposed to DMSO, 8 μM fluconazole, 8.5 mM Caffeine, or 26 μM of ketoconazole. Strains were then allowed to grow on a

Table 2
Strains and plasmids used in this work

Strain	Genotype	Reference
WT (BWP17+Clp30)	<i>ura3Δ::λimm434/ura3::λimm434</i> <i>arg4::hisG/arg4::hisG</i> <i>his1::hisG/his1::hisG + Clp30</i>	(68)
<i>gpc1Δ/Δ</i>	<i>orf19.988Δ::ARG4/</i> <i>orf19.988Δ::HIS1</i> + Clp10 (Ura3)	(22)
<i>gpc1Δ/Δ+Gpc1</i>	<i>orf19.988Δ::ARG4/</i> <i>orf19.988Δ::HIS1 +</i> Clp10/ <i>GPC1</i> (orf19.988, Ura3)	This study
SC5314	Prototrophic WT strain	(69)
<i>ept1Δ/Δ</i>	<i>ept1Δ/Δ-FRT</i>	(11)
<i>pem1Δ/Δpem2Δ/Δ</i>	<i>pem1Δ/Δpem2Δ/Δ-FRT</i>	(11)
Plasmid Clp10		(70)
Clp10+Gpc1		This study

Molecular Devices SpectraMax i3 at 30 °C with intermittent shaking. Data are displayed as the mean and standard deviation of at least three replicates per strain. Every 30 min $A_{600\text{nm}}$ readings were taken, and time zero values were subtracted from each time point to reflect overall growth. Each curve reflects a minimum of three biological replicates (13).

To perform reinoculation growth assays, 5 ml cultures in YPD were grown in triplicate to log phase. Next, DMSO, 14 μg/ml myriocin, or 7 μg/ml miltefosine was added for 1 h. After drug exposure, cells were harvested, washed, and used to restart new overnight cultures at an $A_{600\text{nm}}$ of 0.1. Following 20 h of growth at 30 °C in a roller drum, $A_{600\text{nm}}$ readings were taken.

In vitro enzyme assays

Microsomes were extracted as described (15, 61) with the use of zirconia/silica beads. The microsomal assays were modified from (15). Briefly, 20 μg of microsomal protein was incubated with 200 nmol of ^{14}C -GPC and 10 nmol of acyl-CoA in a total volume of 50 μl for 16 min. The microsomal assays were terminated by addition of 150 μl of 0.15 M acetic acid and 500 μl of $\text{CHCl}_3\text{:MeOH}$ (1:1, v/v), vortexed and centrifuged. The chloroform phase was removed, and an aliquot was taken for liquid scintillation counting (LSC). The remaining chloroform phase was applied on TLC plate (Silica 60, Merck) together with standards for lysophosphatidylcholine and PC. The plate was developed in $\text{CHCl}_3\text{:MeOH:HAc:H}_2\text{O}$ (90:20:20:3 v/v/v/v) and thereafter stained in iodine to visualize the lipids. Lysophosphatidylcholine and PC were scraped off as well as the rest of the sample lane, and the silica gel fractions were counted by LSC. Absolute amounts of radioactivity in each spot were calculated from the total amount of radioactivity in the chloroform phase.

In vivo ^{14}C -choline-glycerophosphocholine radiolabeling and metabolite analysis

Strains were grown to log phase ($A_{600\text{nm}} \approx 0.8$) in YNB medium, at which point ^{14}C -choline-GPC ($\approx 100,000$ cpm/ml) (American Radiolabeled Chemicals 3880) was added. After 1 h of growth in the presence of label, cultures were harvested and the cell pellets were treated with 5% TCA for 20 min on ice. The suspension was pelleted, and aliquots of both the pellet (containing membrane) and the water-soluble TCA extract were subjected to LSC using a Tri-Carb 4910 TR liquid scintillation analyzer (PerkinElmer) as described (13). Lipids were extracted from the membrane fraction and subject to TLC followed by phosphoimager to confirm PC as the sole labeled lipid as described (15). Choline-containing metabolites were separated using anion exchange chromatography as described (62).

Lipidomic analyses

Cultures were grown to logarithmic phase in YNB medium, and 20 optical density units were harvested. For lipid extractions, the cell pellets were treated with 5% TCA for 20 min on ice. Following centrifugation, the supernatant was discarded and cell pellets were incubated at 60 °C for 60 min with 1 ml of ESOAK (95% ethanol, diethyl ether, H_2O , pyridine, NH_4OH (28–30%); 15:5:15:1:0.036 v/v/v/v/v) (63). The tubes were centrifuged to

The *Gpc1* acyltransferase impacts cellular function

pellet the debris, and 1 ml of lipid-containing supernatant was transferred to fresh tubes containing 2.5 ml of chloroform/methanol (2:1) and 0.25 ml of 0.1 M HCl. Following vortexing and low-speed centrifugation, the bottom layers containing glycerophospholipids were dried under N₂ and frozen (13). Glycerophospholipids were then analyzed using electrospray ionization tandem mass spectrometry (ESI-MS²) at the Kansas Lipidomics Research Center as described (64). The internal standards were 0.6 nmol di12:0-phosphatidylcholine (PC), 0.6 nmol di24:1-PC, 0.6 nmol 13:0-lysoPC, 0.6 nmol 19:0-lysoPC, 0.3 nmol di12:0-phosphatidylethanolamine (PE), 0.3 nmol di23:0-PE, 0.3 nmol 14:0-lysoPE, 0.3 nmol 18:0-lysoPE, 0.3 nmol di14:0-phosphatidic acid (PA), 0.3 nmol di20:0(phytanoyl)-PA, 0.3 nmol di14:0-phosphatidylglycerol (PG), 0.3 nmol di20:0(phytanoyl)-PG, 0.2 nmol di14:0-phosphatidylserine (PS), 0.2 nmol di20:0(phytanoyl)-PS, 0.23 nmol 16:0–18:0-phosphatidylinositol (PI), and 0.16 nmol di18:0-PI. The signals from these standards were quantified and used in normalization to account for ionization differences among classes.

RNA extraction and real-time quantitative RT-PCR

RNA was extracted from 10 optical density units of cells using the hot phenol extraction protocol (13). RNA integrity was confirmed on an agarose gel. A Thermo Scientific NanoDrop One was used to quantify RNA concentrations. Total RNA (1 µg) was converted to cDNA using a Thermo Scientific Verso cDNA synthesis kit. cDNA conversion was confirmed *via* generic PCR setup with *ACT1* primers, followed by visualization on an agarose gel. Real-time quantitative RT-PCR was performed with a Thermo Scientific Maxima SYBR Green/ROX qPCR Master Mix (2X) using primers listed in Table 3. All data were normalized to *ACT1* using a $\Delta\Delta CT$ analysis method. Real-time quantitative RT-PCR data are graphed as averages of three technical replicates for each of three independent cultures \pm SD. Two-sided *t* tests assuming unequal variance were performed to determine significance. The following notation is used for all figures: **p* \leq 0.05; ***p* \leq 0.005; ****p* \leq 0.0005; *****p* \leq 0.0001.

Stationary phase survival and PI staining

Cultures of indicated strains were inoculated at an $A_{600nm} \sim 0.1$ in YNB medium and allowed to grow for 5 days. Stationary phase survival was assessed through reinoculation growth and through propidium iodide (PI) staining. An aliquot of 5-day-old cells was used to inoculate fresh cultures at an $A_{600nm} \sim 0.1$. The A_{600nm} was determined after 20 h. For PI staining, cells were exposed to 25 µg/ml propidium iodide for 30 min at 30 °C. Cells were then imaged using a Nikon TiE

inverted microscope (Nikon Instruments), with an Orca Flash 4.0 CMOS camera (Hamamatsu) and 100X objective (NA 1.49). Image acquisition was obtained using NIS-Elements software (Nikon). The PI-positive cells were quantified.

Embedded hyphal growth assay

Cells were grown in YPD overnight, and approximately 150 cells from each culture were mixed with molted yeast peptone sucrose and plated (36). Plates were incubated at 25 °C for 4 days. Colonies were imaged using a Nikon SMZ25 stereo-compound microscope with the 2X SHR Plan Apo objective. Image acquisition was obtained using NIS-Elements software (Nikon).

Identification of *Gpc1* homologs

Homologs of ScGpc1 were identified with a blastp search of known and predicted proteins in the NCBI nr database (65). Percent identity is reported. T-Coffee was used to create all sequence alignment using Jalview (66, 67).

Statistical analysis

The *t* test and one- and two-way ANOVA analyses were performed to establish significance using GraphPad Prism 8.

Data availability

Data available upon request to Jana Patton-Vogt (pattonvogt@duq.edu).

Acknowledgments—We would like to thank Todd Reynolds for the *pem1Δ/Δpem2Δ/Δ* and *ept1Δ/Δ* strains.

Funding and additional information—This work was supported by National Institute of Health Grant NIH R15 GM104876 to J. P.-V. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

Conflict of interest—The authors declare that they have no conflicts of interest with the contents of this article.

Abbreviations—The abbreviations used are: CDP, cytidine diphosphate; DRP, phosphatidylcholine deacylation/reacylation pathway; GPC, glycerophosphocholine; LSC, liquid scintillation counting; PC, phosphatidylcholine; PC-PE, phosphatidylethanolamine; PS, phosphatidylserine; TCA, trichloroacetic acid; YNB, yeast nitrogen base; YPD, yeast peptone dextrose.

Table 3
Real-time quantitative RT-PCR primers

Primers	
ACT1Fwd	ATTCGGTGAGTAATCCTA
ACT1Rvs	GTATAGTCCAGATAACAACA
GPC1FWD	TGTGGAGCATTGTGGTGTT
GPC1RVS	AACGCTTCCATTCACCTGGTC

References

1. Nobile, C. J., and Johnson, A. D. (2015) *Candida albicans* biofilms and human disease. *Annu. Rev. Microbiol.* **69**, 71–92
2. Burgess, T. B., Condliffe, A. M., and Elks, P. M. (2022) A fun-guide to innate immune responses to fungal infections. *J. Fungi (Basel)* **8**, 805
3. Firacative, C. (2020) Invasive fungal disease in humans: are we aware of the real impact? *Mem. Inst. Oswaldo Cruz.* **115**, 1–9
4. Lee, Y., Puumala, E., Robbins, N., and Cowen, L. E. (2021) Antifungal drug resistance: molecular mechanisms in *Candida albicans* and beyond. *Chem. Rev.* **121**, 3390

5. Robbins, N., Caplan, T., and Cowen, L. E. (2017) Molecular evolution of antifungal drug resistance. *Annu. Rev. Microbiol.* **71**, 753–775
6. Kaur, J., and Nobile, C. J. (2023) Antifungal drug-resistance mechanisms in *Candida* biofilms. *Curr. Opin. Microbiol.* **71**, 102237
7. Liu, M., Chen, M., and Yang, Z. (2017) Design of amphotericin B oral formulation for antifungal therapy. *Drug Deliv.* **24**, 1–9
8. Nishimoto, A. T., Sharma, C., and Rogers, P. D. (2020) Molecular and genetic basis of azole antifungal resistance in the opportunistic pathogenic fungus *Candida albicans*. *J. Antimicrob. Chemother.* **75**, 257–270
9. Alim, D., Sircaik, S., and Panwar, S. L. (2018) The significance of lipids to biofilm formation in *Candida albicans*: an emerging perspective. *J. Fungi (Basel)* **4**, 140
10. Rella, A., Farnoud, A. M., and Del Poeta, M. (2016) Plasma membrane lipids and their role in fungal virulence. *Prog. Lipid Res.* **61**, 63–72
11. Tams, R. N., Cassilly, C. D., Anaokar, S., Brewer, W. T., Dinsmore, J. T., Chen, Y. L., et al. (2019) Overproduction of phospholipids by the Kennedy pathway leads to hypervirulence in *Candida albicans*. *Front. Microbiol.* **10**, 86
12. Henry, S. A., Kohlwein, S. D., and Carman, G. M. (2012) Metabolism and regulation of glycerolipids in the yeast *Saccharomyces cerevisiae*. *Genetics* **190**, 317–349
13. Anaokar, S., Kodali, R., Jonik, B., Renne, M. F., Brouwers, J. F. H. M., Lager, I., et al. (2019) The glycerophosphocholine acyltransferase Gpc1 is part of a phosphatidylcholine (PC)-remodeling pathway that alters PC species in yeast. *J. Biol. Chem.* **294**, 1189–1201
14. Patton-Vogt, J., and de Kroon, A. I. P. M. (2020) Phospholipid turnover and acyl chain remodeling in the yeast ER. *Biochim. Biophys. Acta Mol. Cell Biol. Lipids* **1865**, 158462
15. Glab, B., Beganovic, M., Anaokar, S., Hao, M. S., Rasmusson, A. G., Patton-Vogt, J., et al. (2016) Cloning of glycerophosphocholine acyltransferase (GPCAT) from fungi and plants: a novel enzyme in phosphatidylcholine synthesis. *J. Biol. Chem.* **291**, 25066–25076
16. Ayyash, M., Algahmi, A., Gillespie, J., and Oelkers, P. (2014) Characterization of a lysophospholipid acyltransferase involved in membrane remodeling in *Candida albicans*. *Biochim. Biophys. Acta Mol. Cell Biol. Lipids* **1841**, 505–513
17. Athenstaedt, K. (2021) Phosphatidic acid biosynthesis in the model organism yeast *Saccharomyces cerevisiae* - a survey. *Biochim. Biophys. Acta Mol. Cell Biol. Lipids* **1866**, 158907
18. Gabaldón, T., Naranjo-Ortiz, M. A., and Marcet-Houben, M. (2016) Evolutionary genomics of yeast pathogens in the Saccharomycotina. *FEMS Yeast Res.* **16**, 64
19. Moran, G. P., Coleman, D. C., and Sullivan, D. J. (2011) Comparative genomics and the evolution of pathogenicity in human pathogenic fungi. *Eukaryot. Cell* **10**, 34
20. Bishop, A. C., Ganguly, S., Solis, N. V., Cooley, B. M., Jensen-Seaman, M. I., Filler, S. G., et al. (2013) Glycerophosphocholine utilization by *Candida albicans*: role of the Git3 transporter in virulence. *J. Biol. Chem.* **288**, 33939–33952
21. Hrach, V. L., King, W. R., Nelson, L. D., Conklin, S., Pollock, J. A., and Patton-Vogt, J. (2023) The acyltransferase Gpc1 is both a target and an effector of the unfolded protein response in *Saccharomyces cerevisiae*. *J. Biol. Chem.* **299**, 104884
22. Mayer, F. L., Wilson, D., Jacobsen, I. D., Miramón, P., Große, K., and Hube, B. (2012) The novel *Candida albicans* transporter Dur31 is a multi-stage pathogenicity factor. *PLoS Pathog.* **8**, e1002592
23. Esfahani, A., Omran, A. N., Salehi, Z., Shams-Ghahfarokhi, M., Ghane, M., Eyboosh, S., et al. (2022) Molecular epidemiology, antifungal susceptibility, and *ERG11* gene mutation of *Candida* species isolated from vulvovaginal candidiasis: comparison between recurrent and non-recurrent infections. *Microb. Pathog.* **170**, 105696
24. Cacho Teixeira, M., Kumar, R., Prasad, R., Yan, L., Jiang, Y.-Y., Q-z, L., et al. (2018) *NSG2* (ORF19.273) encoding protein controls sensitivity of *Candida Albicans* to Azoles through regulating the Synthesis of C14-Methylated Sterols. *Front. Microbiol.* **9**, 218
25. Reinhard, J., Mattes, C., Váth, K., Radanović, T., Surma, M. A., Klose, C., et al. (2020) A quantitative analysis of cellular lipid compositions during acute proteotoxic ER stress reveals specificity in the production of asymmetric lipids. *Front. Cell Dev. Biol.* **8**, 756
26. Powers, R. W., Kaeberlein, M., Caldwell, S. D., Kennedy, B. K., and Fields, S. (2006) Extension of chronological life span in yeast by decreased TOR pathway signaling. *Genes Dev.* **20**, 174
27. Romila, C. A., Townsend, S. J., Malecki, M., Kamrad, S., Rodríguez-López, M., Hillson, O., et al. (2021) Barcode sequencing and a high-throughput assay for chronological lifespan uncover ageing-associated genes in fission yeast. *Microb. Cell* **8**, 146
28. Rollin-Pinheiro, R., Bayona-Pacheco, B., Domingos, L. T. S., da Rocha Curvelo, J. A., de Castro, G. M. M., Barreto-Bergter, E., et al. (2021) Sphingolipid Inhibitors as an alternative to treat candidiasis caused by fluconazole-resistant strains. *Pathogens* **10**, 856
29. Vila, T., Ishida, K., Seabra, S. H., and Rozental, S. (2016) Miltefosine inhibits *Candida albicans* and non-*albicans Candida* spp. biofilms and impairs the dispersion of infectious cells. *Int. J. Antimicrob. Agents* **48**, 512–520
30. Holtappels, M., Swinnen, E., De Groef, L., Wuyts, J., Moons, L., Lagrou, K., et al. (2018) Antifungal activity of oleylphosphocholine on *in vitro* and *in vivo Candida albicans* biofilms. *Antimicrob. Agents Chemother.* **62**, e01767–e01817
31. Srivastava, A., Sircaik, S., Husain, F., Thomas, E., Ror, S., Rastogi, S., et al. (2017) Distinct roles of the 7-transmembrane receptor protein Rta3 in regulating the asymmetric distribution of phosphatidylcholine across the plasma membrane and biofilm formation in *Candida albicans*. *Cell. Microbiol.* **19**. <https://doi.org/10.1111/cmi.12767>
32. Rajakumar, S., Abhishek, A., Selvam, G. S., and Nachiappan, V. (2020) Effect of cadmium on essential metals and their impact on lipid metabolism in *Saccharomyces cerevisiae*. *Cell Stress Chaperones* **25**, 19–33
33. Enjalbert, B., Smith, D. A., Cornell, M. J., Alam, I., Nicholls, S., Brown, A. J. P., et al. (2006) Role of the Hog1 stress-activated protein kinase in the global transcriptional response to stress in the fungal pathogen *Candida albicans*. *Mol. Biol. Cell* **17**, 1018–1032
34. Sudbery, P. E. (2011) Growth of *Candida albicans* hyphae. *Nat. Rev. Microbiol.* **9**, 737–748
35. Chen, H., Zhou, X., Ren, B., and Cheng, L. (2020) The regulation of hyphae growth in *Candida albicans*. *Virulence* **11**, 337–348
36. Brown, D. H., Giusani, A. D., Chen, X., and Kumamoto, C. A. (1999) Filamentous growth of *Candida albicans* in response to physical environmental cues and its regulation by the unique CZF1 gene. *Mol. Microbiol.* **34**, 651–662
37. Xu, N., Dong, Y. J., Yu, Q. L., Zhang, B., Zhang, M., Jia, C., et al. (2015) Convergent regulation of *Candida albicans* Aft2 and Czf1 in invasive and opaque filamentation. *J. Cell. Biochem.* **116**, 1908–1918
38. Mukherjee, P. K., Seshan, K. R., Leidich, S. D., Chandra, J., Cole, G. T., and Ghannoum, M. A. (2001) Reintroduction of the PLB1 gene into *Candida albicans* restores virulence *in vivo*. *Microbiology* **147**, 2585–2597
39. Leidich, S. D., Ibrahim, A. S., Fu, Y., Koul, A., Jessup, C., Vitullo, J., et al. (1998) Cloning and disruption of caPLB1, a phospholipase B gene involved in the pathogenicity of *Candida albicans*. *J. Biol. Chem.* **273**, 26078–26086
40. Ghannoum, M. A. (2000) Potential role of phospholipases in virulence and fungal Pathogenesis. *Clin. Microbiol. Rev.* **13**, 122–143
41. Theiss, S., Ishdorj, G., Brenot, A., Kretschmar, M., Lan, C. Y., Nichterlein, T., et al. (2006) Inactivation of the phospholipase B gene *PLB5* in wild-type *Candida albicans* reduces cell-associated phospholipase A2 activity and attenuates virulence. *Int. J. Med. Microbiol.* **296**, 405
42. Sonkar, K., Ayyappan, V., Tressler, C. M., Adelaja, O., Cai, R., Cheng, M., et al. (2019) Focus on the glycerophosphocholine pathway in choline phospholipid metabolism of cancer. *NMR Biomed.* **32**, e4112
43. Icol, Y. O., Ozbek, R., Hamurtekin, E., and Ulus, I. H. (2005) Choline status in newborns, infants, children, breast-feeding women, breast-fed infants and human breast milk. *J. Nutr. Biochem.* **16**, 489–499
44. Guasch-Ferré, M., Hu, F. B., Ruiz-Canela, M., Bulló, M., Toledo, E., Wang, D. D., et al. (2017) Plasma metabolites from choline pathway and

The Gpc1 acyltransferase impacts cellular function

- risk of cardiovascular disease in the PREDIMED (Prevention with Mediterranean Diet) study. *J. Am. Heart Assoc.* **6**, e006524
45. Jawale, C. V., and Biswas, P. S. (2021) Local antifungal immunity in the kidney in disseminated candidiasis. *Curr. Opin. Microbiol.* **62**, 1–7
 46. Gallazzini, M., Ferraris, J. D., Kunin, M., Morris, R. G., and Burg, M. B. (2006) Neuropathy target esterase catalyzes osmoprotective renal synthesis of glycerophosphocholine in response to high NaCl. *Proc. Natl. Acad. Sci. U. S. A.* **103**, 15260–15265
 47. Gallazzini, M., Ferraris, J. D., and Burg, M. B. (2008) GDPD5 is a glycerophosphocholine phosphodiesterase that osmotically regulates the osmoprotective organic osmolyte GPC. *Proc. Natl. Acad. Sci. U. S. A.* **105**, 11026–11031
 48. Garcia-Perez, A., and Burg, M. B. (1991) Renal medullary organic osmolytes. *Physiol. Rev.* **71**, 1081–1115
 49. Zablocki, K., Miller, S. P. F., Garcia-Perez, A., and Burg, M. B. (1991) Accumulation of glycerophosphocholine (GPC) by renal cells: osmotic regulation of GPC:choline phosphodiesterase. *Proc. Natl. Acad. Sci. U. S. A.* **88**, 7820–7824
 50. Gallazzini, M., and Burg, M. B. (2009) What's new about osmotic regulation of glycerophosphocholine. *Physiology* **24**, 245–249
 51. Harada, S., Taketomi, Y., Aiba, T., Kawaguchi, M., Hirabayashi, T., Uranbileg, B., et al. (2023) The Lysophospholipase PNPLA7 controls hepatic choline and methionine metabolism. *Biomolecules* **13**, 471
 52. Austin, S., and Mayer, A. (2020) Phosphate homeostasis – A vital metabolic equilibrium maintained through the INPHORS signaling pathway. *Front. Microbiol.* **11**, 1367
 53. Kohler, J. R., Acosta-Zaldívar, M., and Qi, W. (2020) Phosphate in virulence of *Candida albicans* and *J. Fungi (Basel)* **6**, 40
 54. King, W., Acosta-Zaldívar, M., Qi, W., Cherico, N., Cooke, L., Köhler, J. R., et al. (2023) Glycerophosphocholine provision rescues *Candida albicans* growth and signaling phenotypes associated with phosphate limitation. *mSphere*. <https://doi.org/10.1128/msphere.00231-23>
 55. Tams, R. N., Wagner, A. S., Jackson, J. W., Gann, E. R., Sparer, T. E., and Reynolds, T. B. (2020) Pathways that synthesize phosphatidylethanolamine impact *Candida albicans* hyphal length and cell wall composition through transcriptional and posttranscriptional mechanisms. *Infect. Immun.* **88**, e00480–e00519
 56. Davis, S. E., Tams, R. N., Solis, N. V., Wagner, A. S., Chen, T., Jackson, J. W., et al. (2018) *Candida albicans* cannot acquire sufficient ethanolamine from the host to support virulence in the absence of de novo phosphatidylethanolamine synthesis. *Infect. Immun.* **86**, e00815–e00817
 57. Vance, J. E. (2015) Phospholipid synthesis and transport in Mammalian cells. *Traffic* **16**, 1–18
 58. Joyce, L. R., Guan, Z., and Palmer, K. L. (2019) Phosphatidylcholine biosynthesis in Mitis group streptococci via host metabolite scavenging. *J. Bacteriol.* **201**, e00495–e00519
 59. Hanscho, M., Ruckerbauer, D. E., Chauhan, N., Hofbauer, H. F., Krahelec, S., Nidetzky, B., et al. (2012) Nutritional requirements of the BY series of *Saccharomyces cerevisiae* strains for optimum growth. *FEMS Yeast Res.* **12**, 796–808
 60. Huang, M. Y., Cravener, M. C., and Mitchell, A. P. (2021) Targeted genetic changes in *Candida albicans* using transient CRISPR-Cas9 expression. *Curr. Protoc.* **1**, e19
 61. Lager, I., Yilmaz, J. L., Zhou, X. R., Jasieniecka, K., Kazachkov, M., Wang, P., et al. (2013) Plant Acyl-CoA:lysophosphatidylcholine acyltransferases (LPCATs) have different specificities in their forward and reverse reactions. *J. Biol. Chem.* **288**, 36902–36914
 62. Surlow, B. A., Cooley, B. M., Needham, P. G., Brodsky, J. L., and Patton-Vogt, J. (2014) Loss of Ypk1, the yeast homolog to the human serum- and Glucocorticoid-induced protein kinase, accelerates phospholipase B1-mediated phosphatidylcholine deacylation. *J. Biol. Chem.* **289**, 31591–31604
 63. Hanson, B. A., and Lester, R. L. (1980) The extraction of inositol-containing phospholipids and phosphatidylcholine from *Saccharomyces cerevisiae* and *Neurospora crassa*. *J. Lipid Res.* **21**, 309–315
 64. Singh, A., Prasad, T., Kapoor, K., Mandal, A., Roth, M., Welti, R., et al. (2010) Phospholipidome of *Candida*: each species of *Candida* has distinctive phospholipid molecular species. *OMICS* **14**, 665–677
 65. Altschul, S. F., Gish, W., Miller, W., Myers, E. W., and Lipman, D. J. (1990) Basic local alignment search tool. *J. Mol. Biol.* **215**, 403–410
 66. Floden, E. W., Tommaso, P. D., Chatzou, M., Magis, C., Notredame, C., and Chang, J. M. (2016) PSI/TM-Coffee: a web server for fast and accurate multiple sequence alignments of regular and transmembrane proteins using homology extension on reduced databases. *Nucleic Acids Res.* **44**, W339–W343
 67. Waterhouse, A. M., Procter, J. B., Martin, D. M. A., Clamp, M., and Barton, G. J. (2009) Jalview Version 2—a multiple sequence alignment editor and analysis workbench. *Bioinformatics* **25**, 1189
 68. Zakikhany, K., Naglik, J. R., Schmidt-westhausen, A., Holland, G., Schaller, M., and Hube, B. (2007) In vivo transcript profiling of *Candida albicans* identifies a gene essential for interepithelial dissemination. *Cell. Microbiol.* **9**, 2938–2954
 69. Gillum, A. M., Tsay, E. Y. H., and Kirsch, D. R. (1984) Isolation of the *Candida albicans* gene for orotidine-5'-phosphate decarboxylase by complementation of *S. cerevisiae* ura3 and *E. coli* pyrF mutations. *Mol. Gen. Genet.* **198**, 179–182
 70. Munir, A. M., Lee, P. R., Broadbent, I. D., Barelle, C. J., and Brown, A. J. (2000) Clp10, an efficient and convenient integrating vector for *Candida albicans*. *Yeast* **16**, 325–327